Head to Head Comparison: Agenus (NASDAQ:AGEN) & ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Profitability

This table compares ImmunityBio and Agenus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-8,016.83%	N/A	-110.02%
Agenus	-145.89%	N/A	-85.68%

Insider & Institutional Ownership

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 4.6% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

ImmunityBio has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares ImmunityBio and Agenus”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$7.33 million	227.14	-$583.20 million	($0.92)	-2.60
Agenus	$160.43 million	0.46	-$245.76 million	($11.24)	-0.28

Agenus has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for ImmunityBio and Agenus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	1	2	1	3.00
Agenus	0	5	1	0	2.17

ImmunityBio currently has a consensus target price of $13.58, suggesting a potential upside of 468.34%. Agenus has a consensus target price of $10.00, suggesting a potential upside of 215.46%. Given ImmunityBio’s stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Agenus.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

About Agenus

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.